A Kaiser score > 5 with breast MRI demonstrated a 97 percent sensitivity and 87.9 percent specificity for predicting malignancy in patients with BI-RADS 0 or 4 presentations on mammography and breast ultrasound, according to a new study.
Assessing breast MRI scans, pathology and clinical data, the AI-powered TumorSight Risk software reportedly provides five- and 10-year risk for breast cancer recurrence for women with HR+, HER2-negative stage I-IIIA breast cancer.
Incorporation of pseudocapsule presence into a modified Clear Cell Likelihood Score (m-ccLS) was associated with a greater than 11 percent higher AUC in differentiating benign and malignant renal masses on mpMRI, according to a new study.